Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

<strong>Background/objective </strong>The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. <br><strong> Methods <...

Bibliografske podrobnosti
Main Authors:	Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS
Format:	Journal article
Jezik:	English
Izdano:	BMJ Publishing Group 2022

Podobne knjige/članki

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
od: Josef S Smolen, et al.
Izdano: (2022-11-01)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
od: Coates, L, et al.
Izdano: (2018)

Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
od: Coates, LC, et al.
Izdano: (2021)

Ixekizumab in the treatment of psoriatic arthritis
od: Yu. L. Korsakova, et al.
Izdano: (2024-12-01)

Methotrexate in psoriasis and psoriatic arthritis
od: Coates, L, et al.
Izdano: (2020)

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
od: Coates, LC, et al.
Izdano: (2016)

Measuring outcomes in psoriatic arthritis
od: Ogdie, A, et al.
Izdano: (2020)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
od: Weinstein, SM, et al.
Izdano: (2021)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
od: Kavanaugh, A, et al.
Izdano: (2024)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
od: Miller J, et al.
Izdano: (2021-12-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
od: Bruce W. Kirkham, et al.
Izdano: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
od: P.S. Helliwell
Izdano: (2011-09-01)

Psoriatic arthritis
od: FitzGerald, O, et al.
Izdano: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
od: Ogdie, A, et al.
Izdano: (2023)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
od: Coates, LC, et al.
Izdano: (2021)

What should be the primary target of "treat to target" in psoriatic arthritis?
od: Coates, LC, et al.
Izdano: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
od: Helliwell, PS, et al.
Izdano: (2022)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
od: Coates, L, et al.
Izdano: (2020)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
od: Gladman, DD, et al.
Izdano: (2018)

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
od: April W. Armstrong, et al.
Izdano: (2024-05-01)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
od: Atul Deodhar, et al.
Izdano: (2023-08-01)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
od: Ye, W, et al.
Izdano: (2021)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
od: Mease, PJ, et al.
Izdano: (2020)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
od: Coates, LC, et al.
Izdano: (2022)

Considerations for the definition of remission criteria in psoriatic arthritis
od: Mease, P, et al.
Izdano: (2017)

Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
od: April W. Armstrong, et al.
Izdano: (2024-07-01)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
od: Coates, L, et al.
Izdano: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
od: Orbai, A-M, et al.
Izdano: (2019)

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
od: A. M. Dadalova, et al.
Izdano: (2020-11-01)

Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab
od: A. Egeberg, et al.
Izdano: (2022-07-01)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
od: Ye, W, et al.
Izdano: (2021)

Current concepts and unmet needs in psoriatic arthritis
od: Mahmood, F, et al.
Izdano: (2017)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
od: Coates, L, et al.
Izdano: (2017)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
od: Coates, LC, et al.
Izdano: (2024)

Psoriatic arthritis: prospects for the future
od: Hackett, S, et al.
Izdano: (2022)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
od: Yazji, SM, et al.
Izdano: (2025)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
od: Leung, Y-Y, et al.
Izdano: (2023)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
od: Helliwell, PS, et al.
Izdano: (2021)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
od: Coates, LC, et al.
Izdano: (2018)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
od: Coates, L, et al.
Izdano: (2016)